Abilify And Six New Drugs Push Otsuka’s 2012 Results Up 7.8%
This article was originally published in PharmAsia News
Otsuka Holdings announced 2012 Japan sales results of ¥351.8 billion ($3.4 billion), a 7.8% increase from the previous year.
You may also be interested in...
A bill adopted by the US Senate marks the latest bipartisan move to tighten the country's grip over companies from China seeking an initial public offering, adding further uncertainty over such plans in the US.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.